Icatibant Universal Farma

Icatibant, the active ingredient in Icatibant Universal Farma, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency, providing rapid reduction of swelling and associated discomfort.

GNH USA supplies Icatibant Universal Farma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance and timely delivery to global markets.

Icatibant acts on the bradykinin pathway to relieve hereditary angioedema symptoms.

- Hereditary angioedema type I: rapid reduction of swelling and pain during acute attacks, often within minutes of administration. - Hereditary angioedema type II: alleviates edema and associated discomfort during flare‑ups, helping restore normal function. - Hereditary angioedema with normal C1‑inhibitor: provides effective symptom control during acute episodes, reducing airway and peripheral swelling.

Icatibant may cause a range of adverse reactions, most of which are related to its subcutaneous administration.

Common Side Effects: - Injection site pain: mild discomfort. - Redness: localized erythema. - Swelling: transient edema. - Nausea: occasional queasiness. - Headache: mild to moderate. - Dizziness: brief light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity: rash or hives. - Anaphylaxis: severe allergic reaction. - Severe hypotension: sudden blood‑pressure drop. - Paradoxical angioedema: worsening swelling. - Thrombocytopenia: low platelet count. - Urticaria: widespread hives.

Before using Icatibant, consider the following precautions to ensure safe administration.

- Allergy assessment: verify no known hypersensitivity to icatibant or formulation components. - Pregnancy: safety not established; use only if potential benefit justifies risk. - Breastfeeding: unknown excretion; weigh benefits against possible infant exposure. - Renal impairment: no dosage adjustment required, but monitor for accumulation of adverse effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence bradykinin levels or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin and exacerbate angioedema. - Concomitant B2 receptor antagonists: additive blockade could alter efficacy.

Moderate Interactions (Monitor Closely): - Estrogen‑containing oral contraceptives: may raise attack frequency; monitor symptoms. - NSAIDs: can trigger angioedema in susceptible individuals; observe closely. - C1‑inhibitor concentrate administered simultaneously: may affect therapeutic response; coordinate timing.